Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 3,455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matching Oral Placebo Clear all
Completed Phase 3 Interventional Results available

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

NCT00073307
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
903 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
31
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 14, 2026, 2:30 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Phase 2 Interventional

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

NCT06617312
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Disorder
Interventions
Cytisinicline, Placebo Oral Capsule
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 14, 2026, 2:30 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

NCT05650112
View directory record Official record
Conditions
Healthy, Enteric Hyperoxaluria
Interventions
FB-001, Placebo
Biological
Lead sponsor
Federation Bio Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

NCT00602030
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Interventions
Entinostat, Placebo, Erlotinib
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
30
States / cities
Tucson, Arizona • Denver, Colorado • Miami, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

NCT05795907
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions
SAR443820, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Phase 2 Interventional

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

NCT05928936
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium Bicarbonate, Exercise Training, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
40 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

NCT03566511
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Diazoxide, Placebo
Drug
Lead sponsor
Meredith Hawkins
Other
Eligibility
21 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Phase 3 Interventional

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

NCT03922607
View directory record Official record
Conditions
Psoriasis
Interventions
ABBV-157, Placebo for ABBV-157
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)

NCT03616964
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

NCT03485911
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
BCX7353 capsules, Placebo oral capsule
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 14, 2026, 2:30 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

NCT07455383
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

NCT00592553
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy
Interventions
Ataluren, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
5 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Sacramento, California • Aurora, Colorado • Pensacola, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 14, 2026, 2:30 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina

NCT04306237
View directory record Official record
Conditions
Refractory Angina
Interventions
IMB-1018972, Placebo oral tablet
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 2 Interventional

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT06335303
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 1819479, Placebo matching BI 1819479
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Not listed Phase 3 Interventional

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

NCT02858453
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
Interventions
AQX-1125 100 mg, AQX-1125 200 mg, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
56
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2018 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 2 Interventional Results available

Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease

NCT01590888
View directory record Official record
Conditions
Huntington Disease
Interventions
PBT2, Placebo
Drug
Lead sponsor
Prana Biotechnology Limited
Industry
Eligibility
25 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
14
States / cities
San Diego, California • Englewood, Colorado • Farmington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 2 Interventional Results available

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

NCT04104646
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
CHF6563, Morphine, CHF6563 matched placebo, Morphine matched placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
Up to 7 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Las Vegas, Nevada • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

NCT00680186
View directory record Official record
Conditions
Thromboembolism
Interventions
Warfarin, Dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 14, 2026, 2:30 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathy
Interventions
LP352, Placebo
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 14, 2026, 2:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

NCT05366439
View directory record Official record
Conditions
Dengue
Interventions
AT-752, Placebo Comparator
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 14, 2026, 2:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

NCT00286442
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and metformin, Metformin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Artesia, California + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 14, 2026, 2:30 AM EDT